North Coast Biologics

North Coast Biologics was a private Seattle-area antibody discovery company focused on generating antibody therapeutics, diagnostics, and target-validation reagents. Public company-profile databases describe the company as developing antibodies for infectious disease, autoimmune disease, cancer, and veterinary applications, and identify its proprietary BLAST (B-Lymphoblast Activation and Selection Technology) platform for selecting antibodies from non-immortalized B cells. Available third-party pipeline data indicate at least one disclosed preclinical/discontinued LAG-3-targeting monoclonal antibody program. The company appears to have remained very small and unfunded, and multiple sources indicate it is no longer active. The business is also associated with regulatory and legal actions tied to misleading COVID-19-related claims by its founder.